Omega Laboratories Hair Drug Screening Assay Methamphetamine (Meth) and -3, 4-methylenedioxymethamphetamine (MDMA)

K142855 · Omega Laboratories, Inc. · DKZ · Jul 28, 2015 · Clinical Toxicology

Device Facts

• Record ID: K142855
• Device Name: Omega Laboratories Hair Drug Screening Assay Methamphetamine (Meth) and -3, 4-methylenedioxymethamphetamine (MDMA)
• Applicant: Omega Laboratories, Inc.
• Product Code: DKZ · Clinical Toxicology
• Decision Date: Jul 28, 2015
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 862.3100
• Device Class: Class 2

Indications for Use

The Omega Laboratories Hair Drug Screening Assay for Methamphetamine (Meth) and 3,4-Methylenedioxymethamphetamine (MDMA) is an in vitro diagnostic test that is intended for the qualitative detection of Methamphetamine (calibrated with Methamphetamine) and MDMA (calibrated with MDMA) at or above 500 pg/mg in human head and body hair. To confirm a screen positive result, a more specific alternate chemical method, such as Gas Chromatography/Mass Spectrometry (GC/MS) operating in the selected ion monitoring (SIM) mode with deuterated internal standards is the preferred method. Professional judgment should be applied to any drug of abuse test result, particularly when presumptive positive results are obtained. This test is intended exclusively for single laboratory use only and is not intended for sale to anyone.

Device Story

Device is an in vitro diagnostic ELISA-based screening assay for qualitative detection of Methamphetamine and MDMA in human head and body hair. Input: hair samples (head/body). Process: hair is pulverized (patent-pending method) and extracted using acid-methanol; ELISA reagents and microplate reader (450 nm) used for analysis. Output: qualitative screen result (positive/negative). Used in a single laboratory setting by laboratory personnel. Presumptive positive results require confirmation via GC/MS (SIM mode with deuterated internal standards). Professional judgment is required for interpretation. Benefits: provides historical drug use information; aids in identifying drug use.

Clinical Evidence

No clinical studies performed. Bench testing only. Method comparison study conducted on 138 body hair samples (69 Methamphetamine, 69 MDMA) compared against GC/MS reference method; results were acceptable. Analytical specificity testing performed on structurally similar compounds (Ephedrine, Phentermine, etc.) at concentrations up to 400,000 pg/mg.

Technological Characteristics

Qualitative ELISA immunoassay. Components: rabbit anti-BE polyclonal antibody-coated micro-wells, HRP-conjugated drug substrate, wash solution. Extraction: acid-methanol. Measurement: automated microplate reader (450 nm/630 nm). Cut-off: 500 pg/mg. Single laboratory use.

Indications for Use

Indicated for qualitative detection of Methamphetamine and MDMA at or above 500 pg/mg in human head and body hair. Intended for single laboratory use only.

Regulatory Classification

Identification

An amphetamine test system is a device intended to measure amphetamine, a central nervous system stimulating drug, in plasma and urine. Measurements obtained by this device are used in the diagnosis and treatment of amphetamine use or overdose and in monitoring levels of amphetamine to ensure appropriate therapy.

Special Controls

*Classification.* Class II (special controls). An amphetamine test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (*e.g.,* programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).

Predicate Devices

• Omega Laboratories Hair Drug Screening Assay for Methamphetamine and 3, 4-Methylenedioxymethamphetamine (k101973)

Submission Summary (Full Text)

{0}

1

# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number:
k142885

B. Purpose for Submission:
Addition of body hair claim to a previously cleared test

C. Measurand:
Methamphetamine (Meth) and 3,4-Methylenedioxymethamphetamine (MDMA) in hair

D. Type of Test:
Qualitative ELISA Immunoassay

E. Applicant:
Omega Laboratories, Inc.

F. Proprietary and Established Names:
Omega Laboratories Hair Drug Screening Assay for Methamphetamine (Meth) and 3,4-Methylenedioxymethamphetamine (MDMA)

G. Regulatory Information:
1. Regulation section:
21 CFR §862.3610, Methamphetamine Test System
2. Classification:
Class II
3. Product code:
DKZ – Enzyme Immunoassay, Methamphetamine

{1}

4. Panel:

Toxicology (91)

H. Intended Use:

1. Intended use(s):

See indications for use below.

2. Indication(s) for use:

The Omega Laboratories Hair Drug Screening Assay for Methamphetamine (Meth) and 3,4-Methylenedioxymethamphetamine (MDMA) is an in vitro diagnostic test that is intended for the qualitative detection of Methamphetamine (calibrated with Methamphetamine) and MDMA (calibrated with MDMA) at or above 500 pg/mg in human head and body hair. To confirm a screen positive result, a more specific alternate chemical method, such as Gas Chromatography/Mass Spectrometry (GC/MS) operating in the selected ion monitoring (SIM) mode with deuterated internal standards is the preferred method. Professional judgment should be applied to any drug of abuse test result, particularly when presumptive positive results are obtained.

This test is intended exclusively for single laboratory use only and is not intended for sale to anyone.

3. Special conditions for use statement(s):

The assay provides only a preliminary analytical test result. A more specific alternate chemical method, such as Gas Chromatography/Mass Spectrometry (GC/MS) operating in the selected ion monitoring (SIM) mode with deuterated internal standards is the preferred method. Professional judgment should be applied to any drug of abuse test result, particularly when presumptive positive results are obtained.

4. Special instrument requirements:

The screening assay is for use with an automated microplate reader capable of measuring at 450 and 630 nm.

I. Device Description:

The assay consists of two parts; a pre-analytical hair treatment procedure (to extract methamphetamine and MDMA from the solid hair matrix to a measurable liquid matrix), and the screening assay. The screening assay is an Enzyme-Linked ImmunoSorbent Assay (ELISA).

The Hair Drug Screening Assay for Methamphetamine (Meth) and 3,4-Methylenedioxymethamphetamine (MDMA) uses the International Diagnostic Systems Corp

2

{2}

(IDS) One-Step ELISA Methamphetamine micro-plate/reagents and a micro-plate reader for the qualitative detection of Methamphetamine in hair samples. The test system consists of micro strip plates coated with rabbit anti-BE polyclonal antibody, enzyme conjugate (horseradish peroxidase conjugated to Methamphetamine substrate (containing tetramethylbenzidine), and wash solution. Cut off concentration is 500 pg/mg hair.

## J. Substantial Equivalence Information:

1. Predicate device name(s):

Omega Laboratories Hair Drug Screening Assay for Methamphetamine and 3, 4-Methylenedioxymethamphetamine

2. Predicate 510(k) number(s):

k101973

3. Comparison with predicate:

| Similarities and Differences | | |
| --- | --- | --- |
| Item | Device | k101973 Predicate |
| Laboratory | Omega Laboratories | Same |
| Indication for/Intended Use | Same except for head and body hair | Intended to be used for the qualitative determination of the presence of Methamphetamine and 3,4-Methylenedioxymethamphetamine (MDMA) in human hair from the head. |
| Method of Measurement | Same | Microplate Reader read at 450 nm |
| Matrix | Head and body hair | Head hair |
| Cut-off Concentration | Same | 500 pg Methamphetamine and MDMA /mg hair |
| Assay Principal | Same | ELISA |
| Extraction Method | Same | Acid-methanol to facilitate extraction of Methamphetamine and 3,4-Methylenedioxymethamphetamine (MDMA from hair. Hair is pulverized into small segments prior to acid-methanol extraction, which improves extraction times without loss of efficiency |

{3}

K. Standard/Guidance Document Referenced (if applicable):

None referenced

L. Test Principle:

The test consists of two parts; a pre-analytical hair treatment procedure (to remove Methamphetamine and MDMA from the solid hair matrix to a measurable liquid matrix), and the screening assay. The screening assay is an Enzyme-Linked ImmunoSorbent Assay (ELISA). Sample is added to a well of the micro strip plate and enzyme conjugate is added, followed by incubation. During this phase the enzyme-labeled drug conjugate competes with drug in the sample for a limited number of binding sites on the rabbit antibody-coated micro wells. The two bind in proportion to their concentrations. A wash solution is applied to remove any unbound materials.

Enzyme substrate solution containing a chromagen is added. The reaction is stopped with an acid and the absorbance is read using a plate reader at 450 nm and a background reading is also taken at 630 nm. Color intensity is inversely proportional to the amount of drug present in the sample.

M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

See k101973

b. Linearity/assay reportable range:

Not applicable

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

See k101973 for control stability, hair sample stability, and shipping stability information.

d. Detection limit:

See k101973

e. Analytical specificity:

See k101973 for cross reactivity, interference (structurally related and unrelated compounds), hair treatment, and environmental contamination studies.

{4}

In addition to studies conducted in k101973, the sponsor performed additional cross reactivity testing on several structurally similar compounds including $((+/-) 2, 5$-Dimethoxy-4-Bromoamphetamine, 1S, 2R (+) Ephedrine, Phentermine, R(+) Methcathinone, and R, R (-)-Pseudoephedrine). These compounds appeared to contribute to a Methamphetamine or MDMA positive ELISA result at $-50\%$ cutoff, but did not show cross reactivity when tested at concentrations up to $400,000~\mathrm{pg/mg}$.

To investigate this discrepancy, cross reactivity was tested at up to 10 fold higher concentrations. Expected results were obtained. The results are summarized in the tables below. The tables below are also included in the device labeling.

| Compound | Concentration of Compound (pg/mg) Equivalent to 500 pg/mg Methamphetamine Cutoff Control | Percent Cross-Reactivity (%) |
| --- | --- | --- |
| S(+) Methamphetamine | 500.0 | 100.0 |
| (+/-)2,5-Dimethoxy-4bromoamphetamine | 2,000,000.0 | 0.03 |
| 1S,2R(+) Ephedrine | 900,000.0 | 0.06 |
| Phentermine | 600,000.0 | 0.08 |
| R(+) Methcathinone | 900,000.0 | 0.06 |
| R,R(-) Pseudoephedrine | 1,500,000.0 | 0.03 |

f. Assay cut-off:

See k101973

2. Comparison studies:

a. Method comparison with predicate device:

A total of 138 body hair samples (69 each of Methamphetamine and MDMA samples) were tested and compared to the results from GC/MS drug analysis. These

{5}

samples included samples near the cutoff concentration, and positive samples for both MDMA and Methamphetamine. Results were acceptable.

b. Matrix comparison:
Not applicable

3. Clinical studies:
a. Clinical Sensitivity:
Not applicable
b. Clinical specificity:
Not applicable
c. Other clinical supportive data (when a. and b. are not applicable):
Not applicable

4. Clinical cut-off:
Not applicable

5. Expected values/Reference range:
Not applicable

N. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

O. Conclusion:
The submitted information in this premarket notification is complete and supports a substantial equivalence decision.